Related Experiment Video
Updated: Jun 23, 2025

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.7K
Cutaneous metastases: From epidemiology to therapy
Martin Gschnell1, Christian Volberg2,3, Christina Hauser1
1Department of Dermatology and Allergology, University Hospital of Marburg, Philipps University Marburg, Marburg, Germany.
Summary
Cutaneous metastases, skin spread of cancer, affect up to 10% of oncology patients. This review covers diagnostic and therapeutic strategies for managing these challenging skin conditions.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Cutaneous metastases are a significant clinical manifestation in oncology, affecting up to 10% of cancer patients.
- These skin metastases can lead to substantial psychological distress, including shame and social withdrawal, particularly when exulcerated.
- The location and presentation of cutaneous metastases vary depending on the primary cancer type.
Purpose of the Study:
- To provide a comprehensive overview of the diagnostic approaches for cutaneous metastases.
- To review current local and systemic therapeutic options for managing skin metastases.
- To discuss the most common primary tumor entities associated with cutaneous metastases.
Main Methods:
- Literature review of diagnostic and therapeutic strategies for cutaneous metastases.
- Analysis of current research on treatment options based on tumor entity.
- Synthesis of information on the psychological impact and management.
Main Results:
- Cutaneous metastases represent a common occurrence in cancer patients, with diverse clinical presentations.
- Effective diagnostic tools are available to identify skin involvement accurately.
- A range of local and systemic treatments can be employed, tailored to the specific cancer type and patient.
Conclusions:
- Accurate diagnosis and timely management of cutaneous metastases are crucial for improving patient outcomes and quality of life.
- Multidisciplinary approaches are often necessary for optimal treatment planning.
- Further research into novel therapeutic strategies is warranted to address the challenges posed by skin metastases.
Related Concept Videos
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K
Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K

